Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D., M.Sc., Athina Tatsioni, M.D., Ph.D., Efstratios M. Kolibianakis, M.D., Ph.D., Willem Verpoest, M.D., Herman Tournaye, M.D., Ph.D., Josiane Van der Elst, Ph.D., Paul Devroey, M.D., Ph.D.  Fertility and Sterility  Volume 90, Issue 2, Pages 367-372 (August 2008) DOI: 10.1016/j.fertnstert.2007.06.064 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Flow diagram for meta-analysis: abstract identification and selection. Fertility and Sterility 2008 90, 367-372DOI: (10.1016/j.fertnstert.2007.06.064) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 2 (A) Overall results of GnRH antagonist administration vs. control for intrauterine insemination (IUI) timing after a gonadotropin regimen and the odds for pregnancy. (B) Overall results of GnRH antagonist administration vs. control for IUI timing after a gonadotropin regimen and the odds for multiple pregnancy rates. (C) Subgroup analyses for LH rise after GnRH antagonist administration vs. control for IUI timing in a gonadotropin regimen. In all panels, each study is shown as an odds ratio estimate, with whiskers corresponding to 95% confidence intervals, and studies are ordered by year of publication. Fertility and Sterility 2008 90, 367-372DOI: (10.1016/j.fertnstert.2007.06.064) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions